1. Home
  2. GVH vs SKYE Comparison

GVH vs SKYE Comparison

Compare GVH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

N/A

Current Price

$1.29

Market Cap

10.7M

Sector

N/A

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$2.11

Market Cap

9.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GVH
SKYE
Founded
2016
2012
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
9.0M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
GVH
SKYE
Price
$1.29
$2.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$80.00
$15.00
AVG Volume (30 Days)
331.6K
328.0K
Earning Date
02-17-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102,768.97
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.26
52 Week High
$6.46
$4.99

Technical Indicators

Market Signals
Indicator
GVH
SKYE
Relative Strength Index (RSI) 54.76 68.62
Support Level $0.87 $0.66
Resistance Level $1.29 $2.32
Average True Range (ATR) 0.07 0.19
MACD 0.08 0.01
Stochastic Oscillator 54.81 77.05

Price Performance

Historical Comparison
GVH
SKYE

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: